Matthew Fowler

Results from a study evaluating circulating tumor tissue–modified viral (TTMV)–human papillomavirus (HPV) DNA among patients treated for HPV-driven oropharyngeal squamous cell carcinoma is of interest.

Patients with muscle invasive bladder cancer ineligible for cisplatin in cohort H of the phase 1b/2 EV-103 trial demonstrated promising antitumor activity when receiving neoadjuvant enfortumab vedotin.

In a phase 1/2 study demonstrated that the combination of encorafenib, cetuximab, and nivolumab was well tolerated and led to responses in patients with microsatellite stable BRAFV600E metastatic colorectal cancer.

Higher sustained MRD-negativity rates were observed among patients with transplant-eligible newly diagnosed multiple myeloma receiving D-VTd over VTd alone

In patients with high-risk nonmetastatic prostate cancer treatment involving abiraterone acetate and prednisolone with or without enzalutamide added to androgen deprivation therapy for 2 years led to meaningfully enhanced survival outcomes.

Results from the LYRA trial showed that the combination of daratumumab with cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses in patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status.

Daratumumab plus cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses in patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status.

Patients with triple-class exposed relapsed or refractory multiple myeloma demonstrated greater efficacy in terms of response and survival from treatment with ciltacabtagene autoleucel in comparison with the standard of care (SOC) in the CARTITUDE-1 trial, according to findings presented at the 2021 EHA Congress.

Outcomes for patients with relapsed or refractory multiple myeloma who had previously received a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody improved with the use of ciltacabtagene autoleucel as compared with conventional therapies, according to findings from propensity score–matched analyses of the CARTITUDE-1 and MAMMOTH studies.

Efficacy was improved with Lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups over sunitinib.

Over half, 56%, of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who were treated with The combination of ibrutinib plus venetoclax produced a complete response and complete response with incomplete bone marrow recovery

Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with the combination of ibrutinib plus venetoclax had complete response and complete response with a 56% incomplete bone marrow recover rate in the phase 2 CAPTIVATe study.

Based on 7-year follow-up data, the use of front-line ibrutinib monotherapy has sustained progression-free survival and overall survival benefit compared with chlorambucil as treatment of patients with chronic lymphocytic leukemia.

A phase 1 study is the first to demonstrate that JSP191 is safe and effective in older patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.

Long-term follow-up results from KEYNOTE-042 show that pembrolizumab continues to improve survival and response outcomes in patients with PD-L1+ locally advanced or metastatic non–small cell lung cancer.

In patients with esophageal cancer, chemotherapy with or without added pembrolizumab led to similar health-related quality of life results over 18 weeks, according to findings from the phase 3 KEYNOTE-590 study.

The combination of daratumumab with lenalidomide, bortezomib, and dexamethasone followed by maintenance therapy with daratumumab and lenalidomide improved response rates and depth of response rates with statistically significance as treatment of patients with transplant-eligible newly diagnosed multiple myeloma.

Treatment with enzalutamide in combination with androgen deprivation therapy led to a clinically meaningful decrease in the risk of death for patients with non-metastatic castration resistance prostate cancer.

The phase 3 COMBI-I clinical trial of spartalizumab plus dabrafenib and trametinib showed no improvement in investigator-assessed progression-free survival in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma, missing the primary end point in part 3 of the study.

The primary end point of investigator-assessed progression-free survival was missed in part 3 of the randomized, Phase 3 COMBI-i study of spartalizumab in combination with dabrafenib and trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma, according to results presented at the 2020 ESMO Virtual Congress.

"In this trial, [mirvetuximab soravtansine] was combined with bevacizumab for a broader segment of recurrent ovarian cancer patients, regardless of platinum status."

Despite missing the primary end point of progression-free survival improvement, cediranib and olaparib demonstrated comparable activity with platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer.

"Although patient numbers and follow-up were limited, savolitinib demonstrated encouraging efficacy and an improved safety profile versus sunitinib."